Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gntls srl, uzina experimentala - etamsylatum - solutie injectabila - 12,5 %

Uniunea Europeană - română - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - everolimus - comprimate - 2,5 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

fsp materia medica holding srl - o combinatie - comprimate de supt

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

zdorovie narodu srl, if din harkov - chlorpromazinum - solutie injectabila - 25 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lekpharm srl - ramiprilum - comprimate - 10 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lekpharm srl - ramiprilum - comprimate - 5 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unipharm inc. - combinatie - comprimate filmate

Uniunea Europeană - română - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilate - carcinomul, celula renală - agenți antineoplazici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.